Home » Stocks » MRNS

Marinus Pharmaceuticals, Inc. (MRNS)

Stock Price: $15.26 USD 0.54 (3.67%)
Updated May 13, 2021 4:00 PM EDT - Market closed
After-hours: $15.25 -0.01 (-0.07%) May 13, 5:22 PM
Market Cap 559.10M
Revenue (ttm) 1.72M
Net Income (ttm) -76.36M
Shares Out 36.63M
EPS (ttm) -2.80
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $15.26
Previous Close $14.72
Change ($) 0.54
Change (%) 3.67%
Day's Open 14.85
Day's Range 14.72 - 15.72
Day's Volume 239,684
52-Week Range 6.04 - 20.04

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #earnings--Marinus Pharmaceuticals Reschedules First Quarter 2021 Financial Results Conference Call for Monday, May 17 at 8:30 AM Eastern

13 hours ago - Business Wire

RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. plans to release financial results for the first quarter ended March 31, 2021 after the market close on May 13, 2021.

6 days ago - Business Wire

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS--Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences

2 weeks ago - Business Wire

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS--MARINUS PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)

1 month ago - Business Wire

RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals announced Steven E. Pfanstiel as Chief Financial Officer and Lisa Lejuwaan as Vice President of Sales.

1 month ago - Business Wire

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS--Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

1 month ago - Business Wire

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #BOD--Marinus Pharmaceuticals Appoints Dr. Saraswathy (Sara) Nochur to Board of Directors

1 month ago - Business Wire

Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of -5.77% and -12.41%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

RADNOR, Pa.--(BUSINESS WIRE)-- #CDD--Marinus provided an update on its clinical and regulatory development activities and reported its financial results for 4Q

2 months ago - Business Wire

RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc., today unveiled its new brand identity.

2 months ago - Business Wire

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals will participate in multiple investor healthcare and life sciences conferences.

2 months ago - Business Wire

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #earnings--Marinus Pharmaceuticals will release the financial results for the fourth quarter and fiscal year ended December 31, 2020 on March 9 via webcast.

3 months ago - Business Wire

Investors need to pay close attention to Marinus Pharmaceuticals (MRNS) stock based on the movements in the options market lately.

3 months ago - Zacks Investment Research

Marinus (MRNS) gets positive FDA response for phase III Marigold study on oral ganaxolone in children and young adults with CDKL5 deficiency disorder that appears sufficient to support the NDA filing.

3 months ago - Zacks Investment Research

RADNOR, Pa.--(BUSINESS WIRE)-- #CDD--Marinus received a positive response from the FDA on sufficiency of Marigold Study data to support filing of NDA for the use of ganaxolone in CDD.

4 months ago - Business Wire

RADNOR, Pa.--(BUSINESS WIRE)-- #HCWBioConnect--Marinus management will participate in the 39th Annual J.P. Morgan Healthcare Conference and the H.C. Wainwright Bioconnect 2021 Conference.

4 months ago - Business Wire

Here we discuss five biotech stocks - EDIT, VRTX, NTLA, CBAY, MRNS - that could prove to be great investments in the long run.

Other stocks mentioned: CBAY, EDIT, NTLA, VRTX
4 months ago - Zacks Investment Research

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals announced it has been selected for inclusion in the Nasdaq Biotechnology Index (NBI).

4 months ago - Business Wire

This can happen when a company holds out its hand for a big chunk of fresh capital.

Other stocks mentioned: ARCT, IBIO
5 months ago - The Motley Fool

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals announces the pricing of an underwritten public offering of 5 million shares of its common stock for gross proceeds of $70MM.

5 months ago - Business Wire

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals announces an underwritten public offering of its common stock.

5 months ago - Business Wire

RADNOR, Pa.--(BUSINESS WIRE)-- #AES2020--Marinus Pharmaceuticals will provide additional ganaxolone data during #AES2020 Scientific Exhibit.

5 months ago - Business Wire

RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals announced the grant of inducement awards to two new employees.

5 months ago - Business Wire

RADNOR, Pa.--(BUSINESS WIRE)-- #AES2020--Marinus Pharmaceuticals will host a webinar with updates on its programs in status epilepticus, CDD, and TSC at #AES2020.

5 months ago - Business Wire

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #AES2020--Marinus Pharma. to present updates and data from its trials in CDKL5 and refractory status epileptics at American Epilepsy Society's conference.

5 months ago - Business Wire

RADNOR, Pa.--(BUSINESS WIRE)-- #MarinusPharma--Marinus Pharmaceuticals announced the grant of inducement awards to two new employees.

6 months ago - Business Wire

Marinus Pharmaceuticals, Inc. (MRNS) CEO Scott Braunstein on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of 17.74% and -100.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the s...

6 months ago - Zacks Investment Research

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #CDKL5--Marinus Pharmaceuticals provides a business update following its "milestone" third quarter.

6 months ago - Business Wire

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #ChiefCommercialOfficer--Marinus Pharmaceuticals appoints Christy Shafer as Chief Commercial Officer. Shafer will report to CEO Dr. Scott Braunstein, and comes fro...

6 months ago - Business Wire

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #FY2020--Marinus Pharmaceuticals will announce its financial results for the third quarter on November 9, 2020 following the close of market.

6 months ago - Business Wire

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #GuggenheimHealthcareTakes--Marinus Pharmaceuticals announced that company management will participate in a number of investor healthcare conferences from late Oct...

6 months ago - Business Wire

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #BARDA--Marinus Pharmaceuticals has satisfied the FDA's protocol-specific questions for its Phase 3 trial in RSE and announces VPs, Clinical Development.

7 months ago - Business Wire

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS--Marinus Pharmaceuticals announced that it will effect a one-for-four reverse stock split of its common stock at 5:00 pm ET today.

7 months ago - Business Wire

The healthcare sector defied last week's market rout buoyed by the progress in the development of a coronavirus vaccine or treatment, and merger and acquisition news.

Other stocks mentioned: BBC, BTEC, IBBJ, IDNA, NVUS, PTH, SAVA ...
7 months ago - Zacks Investment Research

Find out what's behind their big run-ups to see if they can make it happen again.

Other stocks mentioned: IMMU, VXRT
7 months ago - The Motley Fool

The announcement of positive topline results in a late-stage epilepsy trial prompted a rally in Marinus Pharmaceuticals Inc.

7 months ago - 24/7 Wall Street

Investors are thrilled with the results from a late-stage clinical study of the company's only pipeline drug candidate.

7 months ago - The Motley Fool

Shares of small-cap biopharma Marinus Pharmaceuticals Inc (NASDAQ: MRNS) were moving sharply higher to a new 52-week high Tuesday following the release of positive results for ganaxolone, the only inves...

7 months ago - Benzinga

Marinus Pharmaceuticals (MRNS) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

7 months ago - Zacks Investment Research

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #CDKL5--Marinus Pharmaceuticals' management will present at three investor conferences the week of September 14.

8 months ago - Business Wire

Investors need to pay close attention to Marinus (MRNS) stock based on the movements in the options market lately.

8 months ago - Zacks Investment Research

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #BizUpdate--Marinus Pharmaceuticals provides an update on its clinical development activities and reports financial results for the second quarter of 2020.

9 months ago - Business Wire

Marinus Pharmaceuticals (NASDAQ: MRNS) shares are trading higher on Thursday after the company announced it has received FDA rare pediatric disease designation for Ganaxolone for the treatment of CDKL5 ...

9 months ago - Benzinga

RADNOR, Pa.--(BUSINESS WIRE)-- #CDKL5--Marinus Pharmaceuticals, Inc.

9 months ago - Business Wire

RADNOR, Pa.--(BUSINESS WIRE)-- #ClinicalTrial--Marinus Pharmaceuticals, Inc.

9 months ago - Business Wire

RADNOR, Pa., June 30, 2020 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure di...

10 months ago - GlobeNewsWire

RADNOR, Pa., June 24, 2020 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure di...

10 months ago - GlobeNewsWire

RADNOR, Pa., June 22, 2020 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure di...

10 months ago - GlobeNewsWire

RADNOR, Pa., June 15, 2020 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc.  (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat orphan seizure ...

10 months ago - GlobeNewsWire

About MRNS

Marinus Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing and commercializing therapeutics to treat rare seizure disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in formulations for two routes, including intravenous (IV) and oral for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ganaxolone product candidate, acts at synaptic and extrasynaptic GABAA receptors, a target fo... [Read more...]

Industry
Biotechnology
IPO Date
Jul 31, 2014
Stock Exchange
NASDAQ
Ticker Symbol
MRNS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 10 analysts, the average rating for MRNS stock is "Strong Buy." The 12-month stock price forecast is 29.78, which is an increase of 95.15% from the latest price.

Price Target
$29.78
(95.15% upside)
Analyst Consensus: Strong Buy